A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

The requested reference [215bb7bb16a77aa7ca23ac510a883967765057de] no longer exists in our database. It has been replaced by the current reference: [f571f57e1967080c8a1870d8405d5f940113c580]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The aim of the current trial is to evaluate if combination treatment with venetoclax + ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (RR CLL) can lead to MRD negativity, which may induce long lasting remissions for MRD-negative patients randomized to stopping treatment after 15 induction cycles.
Epistemonikos ID: 3b8412b23674b22751ccebd01d2adb8486d02964
First added on: Mar 19, 2021